Sep 4, 2018
Dr. Niels Riedemann, Co-founder and CEO of InflaRx, discusses the pervasive problem of inflammation in a host of diseases, and how InflaRx is tackling this problem with their clinical-stage antibody therapy, IFX-1. InflaRx believes that they have found the key to addressing inflammation across a range of diseases, in the form of a molecule in the blood, complement factor C5a. Their main focus is on using IFX-1, a monoclonal antibody, to block C5a and prevent its action in patients with hidradenitis suppurativa (HS), a devastating autoimmune disorder that manifests on the skin, to reduce inflammatory lesions and potentially prove an ability of IFX-1 to work in different inflammatory conditions.
#inflammation #InflaRx #complementsystem #HS #immunology #IFX1